Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma
Both the presence and level of ctDNA at baseline, along with persistence of ctDNA within 3 months of starting of treatment, are strong negative prognostic markers in mUM. These findings support the clinical utility of ctDNA as a noninvasive tool for disease monitoring.
Authors
- Daniel J. Smit (ORCID: https://orcid.org/0000-0002-3190-9511)
- Ryan J. Sullivan (ORCID: https://orcid.org/0000-0001-5344-6645)
- Egle Ramelyte (ORCID: https://orcid.org/0000-0001-8262-8608)
- Christoffer Gebhardt (ORCID: https://orcid.org/0000-0001-7090-9584)
- Amélie Ciernik (ORCID: https://orcid.org/0009-0003-4444-4412)
- Julian Kött (ORCID: https://orcid.org/0000-0003-2073-3909)
- Stephany Orjuela (ORCID: https://orcid.org/0000-0002-1508-461X)
- Mitchell Paul Levesque (ORCID: https://orcid.org/0000-0001-5902-9420)
- Isabel Heidrich (ORCID: https://orcid.org/0000-0001-6894-1913)
- Kamaneh Montazeri (ORCID: https://orcid.org/0000-0003-3693-5994)
- Caroline Zellweger (ORCID: https://orcid.org/0000-0001-8459-6371)
- Sandra N. Freiberger (ORCID: https://orcid.org/0000-0001-6874-9649)
- Joanna Mangana (ORCID: https://orcid.org/0000-0003-3962-7575)
- Reinhard Dummer (ORCID: https://orcid.org/0000-0002-2279-6906)
- Aleigha Lawless (ORCID: https://orcid.org/0009-0009-3861-3164)
Institutions
- Union Bank of Switzerland (CH)
- Universität Hamburg (DE)
- University of Zurich (CH)
- Massachusetts General Hospital (US)
- University Hospital of Zurich (CH)
- University Medical Center Hamburg-Eppendorf (DE)
- University Cancer Center Hamburg (DE)
- Biognosys (Switzerland) (CH)
- Center for Cancer Research (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2274
- Primary Topic
- Ocular Oncology and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00